Beyond Narcan: Elysium Aims to Outlast Fentanyl with New Rescue Drug

LYONS, Colo. – January 28, 2026 – As the synthetic opioid crisis continues to evolve into a deadlier and more complex challenge, Colorado-based biopharmaceutical company Elysium Therapeutics has secured $7.5 million in new funding to accelerate a novel overdose rescue therapy. The investment, made through a Simple Agreement for Future Equity (SAFE), will push forward the development of SOOPR™ (Synthetic Opioid Overdose Protection and Reversal), a technology specifically engineered to combat the lethal effects of orally ingested fentanyl and the emerging threat of even more potent nitazenes.

The announcement positions Elysium at the forefront of a critical public health battle, aiming to create a new standard of care for overdose victims in an era where existing interventions are increasingly falling short.

A New Weapon Against a Shifting Epidemic

The landscape of the opioid epidemic has been tragically reshaped by the proliferation of synthetic opioids. Fentanyl, a compound 50 to 100 times more potent than morphine, has become a primary driver of overdose deaths in the United States, claiming over 71,000 lives in 2021 alone and becoming a leading cause of death for Americans aged 18 to 45. The illicit drug supply is now also seeing the rise of nitazenes, a class of synthetic opioids that can be even more powerful than fentanyl.

A particularly insidious challenge that first responders and emergency physicians face is the phenomenon known as "fentanyl rebound" or re-narcotization. This occurs when an overdose victim is revived with a rescue agent like naloxone (widely known by the brand name Narcan), only to have the overdose symptoms return as the rescue drug wears off. Because synthetic opioids like fentanyl can remain in the body for an extended period, especially when ingested orally, the short duration of action of traditional naloxone—typically 30 to 90 minutes—is often insufficient.

Research indicates that an estimated 20% to 45% of overdose victims revived with naloxone experience this dangerous relapse, which can lead to a return of respiratory depression, hypoxic brain injury, and death if not immediately addressed. This gap in care highlights a desperate need for a rescue agent that can match the long-lasting lethality of modern synthetic opioids.

The Science of SOOPR

Elysium Therapeutics believes its SOOPR technology is the answer. Described as a rapid-onset, long-acting rescue agent, SOOPR utilizes a proprietary naloxone prodrug formulation. A prodrug is an inactive compound that the body metabolizes into an active drug, a mechanism that can allow for a more controlled release and a tailored pharmacokinetic profile.

According to the company, SOOPR is designed to offer three key advantages over current treatments:

• Rapid Onset: Preclinical data from in-vivo studies suggest that SOOPR begins working more quickly than both intranasal and intramuscular naloxone, a critical factor when restoring breathing in an overdose victim.
• Extended Duration: The formulation is engineered to provide an effective opioid blockade for 12 to 24 hours. This long window of protection is specifically designed to prevent re-narcotization from oral fentanyl and nitazenes, giving patients and healthcare providers a much greater safety margin.
• Reduced Withdrawal Symptoms: High doses of naloxone or the longer-acting antagonist nalmefene (marketed as Opvee) can induce severe and prolonged precipitated withdrawal, a traumatic experience for the patient. SOOPR aims to mitigate this by delivering naloxone with a unique, "infusion-like" profile that steadily maintains its effect without the harsh peaks and valleys that can trigger severe withdrawal.

"With these funds in place, we have initiated work to progress our SOOPR technology through preclinical and clinical studies as we develop this important, life-saving technology to address the deadly overdose epidemic caused by illicit synthetic opioids," said Greg Sturmer, CEO of Elysium Therapeutics, in a statement. "We believe that our SOOPR technology has enormous potential to become the new standard for rescue and as a countermeasure as the illicit drug market evolves to progressively more dangerous opioids."

By preventing same-day re-use and providing a prolonged period of safety, the technology is also intended to create a crucial opportunity for family members and healthcare professionals to connect the overdose survivor with medically-assisted therapy, which offers the best chance for long-term recovery.

Investment and a Crowded Field

The $7.5 million SAFE investment signals strong investor confidence in Elysium's approach. This type of funding is common for early-stage companies, allowing them to secure capital quickly to reach critical development milestones before a priced equity round. For a biotech firm tackling a public health crisis of this magnitude, it represents a crucial endorsement of both its science and market potential.

The market for overdose reversal agents is active and competitive. The current standard, naloxone, is available in various forms, including the well-known Narcan nasal spray, a higher-dose version called Kloxxado, and the recently approved over-the-counter spray, RiVive. While life-saving, all are based on the same short-acting molecule.

Another competitor, Opvee, uses the antagonist nalmefene, which offers a longer duration of action than naloxone. However, this benefit comes with the significant drawback of potentially causing more severe and prolonged withdrawal symptoms, a factor that can complicate patient care and recovery.

Elysium's SOOPR aims to carve out a unique space by combining the best attributes of existing options—rapid onset and long duration—while minimizing the severe side effects. If successful in clinical trials, it could represent a significant leap forward, offering a more effective and humane intervention for the most challenging overdose cases.

The Path to Market and a Broader Vision

With the new funding, Elysium is charting an ambitious course toward commercialization. The company has already completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) and plans to file its official IND application in 2026 to begin human clinical trials.

The regulatory pathway for a drug addressing such a critical unmet need could be expedited. The FDA has previously used programs like Fast Track and Priority Review to accelerate the approval of vital overdose treatments. Elysium estimates that it could complete all FDA requirements and launch SOOPR within five years of its IND filing, suggesting a potential market debut around 2031, contingent on successful trials and an investment of approximately $50 million for the full development program.

Elysium's mission extends beyond overdose reversal. The company is also developing products under its SMART™ (Safer Medicines Alleviate Risks and Trauma) platform, which aims to build safety features directly into opioid medications. Its O2P™ (oral-overdose protected) hydrocodone has already achieved human proof-of-concept, demonstrating a significant reduction in drug exposure in an overdose scenario compared to generic hydrocodone. This dual focus on both safer pain management and superior overdose rescue underscores a comprehensive strategy to mitigate the harms of the ongoing opioid crisis from multiple angles.